Plasma soluble cluster of differentiation 147 levels are increased in breast cancer patients and associated with lymph node metastasis and chemoresistance

Kuang, Yehong; Liu, Y J; Tang, Lu; Wang, S M; Yan, Guo-Jiao; Liao, Lihong

doi:10.12809/hkmj176865

Cited by 6 publications

(8 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main goal of the present study was to establish if sCD147 could be a prognostic marker in MM. Earlier study showed that serum/plasma sCD147 is elevated in many diseases, including some cancers [36][37][38]43,44] and our earlier studies show that it is elevated in AML [39]. Here, we observed that sCD147 level is significantly higher in MM patients compared to healthy individuals.…”

Section: Discussionsupporting

confidence: 65%

“…Soluble CD147 is thought to support cancer proliferation by interacting with membranebound CD147 [35]. It was shown to be an easily detectable biomarker in some diseases [36][37][38], although its role in haematological malignancies is poorly studied. We recently showed thatsCD147 is overexpressed in acute myeloid leukaemia (AML) patients compared to healthy individuals and that high CD147 is associated with worse overall survival [39].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma

Łacina

Butrym

Frontkiewicz³

et al. 2022

CIMB

View full text Add to dashboard Cite

CD147 (basigin, BSG) is a membrane-bound glycoprotein involved in energy metabolism that plays a role in cancer cell survival. Its soluble form is a promising marker of some diseases, but it is otherwise poorly studied. CD147 is overexpressed in multiple myeloma (MM) and is known to affect MM progression, while its genetic variants are associated with MM survival. In the present study, we aimed to assess serum soluble CD147 (sCD147) expression as a potential marker in MM. We found that sCD147 level was higher in MM patients compared to healthy individuals. It was also higher in patients with more advanced disease (ISS III) compared to both patients with less advanced MM and healthy individuals, while its level was observed to drop after positive response to treatment. Patients with high sCD147 were characterized by worse overall survival. sCD147 level did not directly correlate with bone marrow CD147 mRNA expression. In conclusion, this study suggests that serum sCD147 may be a prognostic marker in MM.

show abstract

Section: Discussionsupporting

confidence: 65%

Section: Introductionmentioning

confidence: 99%

Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma

Łacina

Butrym

Frontkiewicz³

et al. 2022

CIMB

View full text Add to dashboard Cite

show abstract

“…Immunohistological staining demonstrated that expression of CD147 is upregulated in breast cancer tissue, as compared to normal breast tissue [10]. Similar to the expression of MCT1 and MCT4, expression levels of CD147 increase with increasing histological grade [10,15] and positively correlate with poor prognosis and chemoresistance in breast cancer patients [10,23,25]. Transport activity of MCTs can be facilitated by carbonic anhydrase IX (CAIX), an enzyme that has been attributed a central role in tumor acid/base regulation and cancer progression [26][27][28][29][30].…”

Section: Introductionmentioning

confidence: 89%

“…Furthermore, CD147 can induce expression of vascular endothelial growth factors (VEGF) and production of hyaluronan to stimulate angiogenesis [22]. CD147 interacts with the multidrug resistance transporter MDR1 and vacuolar H + -ATPase, thereby promoting chemoresistance [24,25]. Immunohistological staining demonstrated that expression of CD147 is upregulated in breast cancer tissue, as compared to normal breast tissue [10].…”

Section: Introductionmentioning

confidence: 99%

CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells

et al. 2019

View full text Add to dashboard Cite

Tumor cells rely on glycolysis to meet their elevated demand for energy. Thereby they produce significant amounts of lactate and protons, which are exported via monocarboxylate transporters (MCTs), supporting the formation of an acidic microenvironment. The present study demonstrates that carbonic anhydrase IX (CAIX), one of the major acid/base regulators in cancer cells, forms a protein complex with MCT1 and MCT4 in tissue samples from human breast cancer patients, but not healthy breast tissue. Formation of this transport metabolon requires binding of CAIX to the Ig1 domain of the MCT1/4 chaperon CD147 and is required for CAIX-mediated facilitation of MCT1/4 activity. Application of an antibody, directed against the CD147-Ig1 domain, displaces CAIX from the transporter and suppresses CAIX-mediated facilitation of proton-coupled lactate transport. In cancer cells, this "metabolon disruption" results in a decrease in lactate transport, reduced glycolysis and ultimately reduced cell proliferation. Taken together, the study shows that carbonic anhydrases form transport metabolons with acid/base transporters in human tumor tissue and that these interactions can be exploited to interfere with tumor metabolism and proliferation.

show abstract

“…Recently, the interaction between ADAM12 and CD147 was shown to promote the cleavage of CD147 releasing its soluble form in the microenvironment, showing a new way to generate soluble CD147 [31]. A soluble form of CD147 was reported to be associated with tumor growth, metastasis formation and chemoresistance, and has been proposed as a clinical biomarker in breast cancer [32] and hepatocellular carcinoma [33].…”

Section: Cd147 Biological Functions In Cancer: Structure and Partnersmentioning

confidence: 99%

CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker

Landras

Moura

Jouenne

et al. 2019

Cancers

101

View full text Add to dashboard Cite

Microenvironment plays a crucial role in tumor development and progression. Cancer cells modulate the tumor microenvironment, which also contribute to resistance to therapy. Identifying biomarkers involved in tumorigenesis and cancer progression represents a great challenge for cancer diagnosis and therapeutic strategy development. CD147 is a glycoprotein involved in the regulation of the tumor microenvironment and cancer progression by several mechanisms—in particular, by the control of glycolysis and also by its well-known ability to induce proteinases leading to matrix degradation, tumor cell invasion, metastasis and angiogenesis. Accumulating evidence has demonstrated the role of CD147 expression in tumor progression and prognosis, suggesting it as a relevant tumor biomarker for cancer diagnosis and prognosis, as well as validating its potential as a promising therapeutic target in cancers.

show abstract

Plasma soluble cluster of differentiation 147 levels are increased in breast cancer patients and associated with lymph node metastasis and chemoresistance

Cited by 6 publications

References 34 publications

Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma

Soluble CD147 (BSG) as a Prognostic Marker in Multiple Myeloma

CAIX forms a transport metabolon with monocarboxylate transporters in human breast cancer cells

CD147 Is a Promising Target of Tumor Progression and a Prognostic Biomarker

Contact Info

Product

Resources

About